Propanc accelerates plans for Phase 1b first-in-human PRP trial in advanced solid tumors

 Propanc Biopharma accelerates plans for Phase 1b first-in-human PRP trial in advanced solid tumors after new preclinical data

• Lead candidate PRP achieved over 90% tumor growth inhibition in preclinical pancreatic cancer models.
• PRP delivered more than a 2.5-fold survival benefit compared with controls in pancreatic cancer models.

https://finviz.com/stock?t=PPCB&p=d